On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 22, 2023 3:45 pm

QualityStocksNewsBreaks – Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Aspiring to Change the Face of the Oil and Gas Industry

Prospera (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focused on Western Canada, appears poised for record growth. This builds on “the success from 2022, when the company realized a net income of $3.1 million and experienced rapid growth when its revenue grew by a staggering 860% in Q2 2022. Prospera Energy expects significant reductions in production costs through 2024 and sizable increases in daily production. The company is currently exploring strategic acquisition targets to diversify Prospera heavy/light/gas product mix and path to 5,000 BPD over the next 24 months while expanding…

Continue Reading

FridaySep 22, 2023 2:34 pm

QualityStocksNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates into pivotal phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made significant strides in line with this mission,” reads a recent article that discussed attendance by the company’s CEO Wa’el Hashad and EVP and CFO Lisa Locklear at the recent 25th Annual H.C. Wainwright Global Investment Conference. At the…

Continue Reading

FridaySep 22, 2023 1:57 pm

QualityStocksNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Anticipating Growing Demand for UPNEEQ(R)

RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis… UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also…

Continue Reading

FridaySep 22, 2023 1:46 pm

QualityStocksNewsBreaks – SOHM Inc. (SHMN) Expands Team to Direct Global Growth Strategy

SOHM (OTC: SHMN) is a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories. “SOHM is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical and cosmeceutical marketplace… The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins,” a recent article reads. “Dr. Krishna Bhat, MD, Ph.D, FACC, an experienced bioscientist…

Continue Reading

FridaySep 22, 2023 1:38 pm

QualityStocksNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself. PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions,” a recent article reads. “PaxMedica’s lead programs, PAX-101 and PAX-102, utilize…

Continue Reading

FridaySep 22, 2023 1:27 pm

QualityStocksNewsBreaks – Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Carving out Share in Challenger Bank, Crypto Markets

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), through strategic mergers and acquisitions, is helping to accelerate the growth of the challenger bank market. “In turn, the company is making financial services affordable and accessible, particularly to individuals in emerging markets, who grossly lack this access compared to their counterparts in developed regions. This focus is helping FEXD carve out a significant market share and leave an indelible mark, even as the world gradually shifts to digital currency,” reads a recent article. “In a report published by Allied Market Research, it was noted that, in 2019, the global challenger bank market generated…

Continue Reading

FridaySep 22, 2023 11:57 am

QualityStocksNewsBreaks – GEMXX Corp. (GEMZ) Featured in Bell2Bell Podcast

GEMXX (OTC: GEMZ), an enterprise specializing in gold, gemstone and jewelry production, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Richard Clowater, president of GEMXX, joined the program and IBN’s Stuart Smith to provide an introduction of ammolite, an extremely rare gemstone, and discuss the company’s innovative business model. “GEMXX is a mine-to-market enterprise, and we aspire to be fully integrated. This means that we must wear a lot of hats... We’re a resource exploration company, and we have over $800 million in…

Continue Reading

FridaySep 22, 2023 11:05 am

QualityStocksNewsBreaks — Cepton Inc. (NASDAQ: CPTN) CCO Talks Industrializing Lidar with Automotive Programs, Company’s Reverse Stock Split Takes Effect

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is in the spotlight. Cepton’s new chief commercial officer Mitch Hourtienne was a guest during a recent Proactive Investors interview. During the interview, Hourtienne, who has been serving as Cepton senior vice president, and Proactive Investors host Steve Darling discussed his 20-year-plus journey to Cepton as well as his new responsibilities. Hourtienne has worked at several companies, including Sensata, Freescale Semiconductor, Infineon Technologies and Siemens VDO Automotive. Hourtienne explained that at Cepton, he has been involved in securing the company's flagship ADAS lidar series production contract with General…

Continue Reading

ThursdaySep 21, 2023 2:22 pm

QualityStocksNewsBreaks – Electronic Servitor Publication Network Inc. (XESP) Providing Tested Avenues for Elevating Customer Experiences

Electronic Servitor Publication Network (OTC: XESP) is a digital engagement company and a market disruptor offering cutting-edge data analysis and intelligent technology to help enterprises reach their target markets. “Through its managed service, which offers digital activation and engagement solutions, the company looks to provide superior intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, all tested avenues for elevating customer experiences and response. XESP is focused on the use of evolving technologies to increase customer reach and spur organizational growth. The company’s proprietary technology, the Digital Engagement Engine(TM), is an example of its focus on solutions that directly…

Continue Reading

ThursdaySep 21, 2023 2:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-processed glucagon-like peptide-1 (“GLP-1”) drugs such as, but not limited to, semaglutide sold under Novo Nordisk’s brand names Ozempic(R), Wegovy(R) and Rybelsus(R), for purposes of improved  bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. According to the update, Lexaria, through these studies, hopes to achieve superior pharmacokinetic (“PK”) performance using DehydraTECH-powered GLP-1 drugs, which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered